WASHINGTON — The Trump administration is negotiating a deal with drugmakers Eli Lilly and Novo Nordisk that could significantly lower the price of their weight-loss medications and expand coverage through federal health programs, according to new reports from The Wall Street Journal and NBC News.

People familiar with the discussions told The Wall Street Journal the agreement would make the lowest doses of the drugs available through the administration’s TrumpRx initiative for as little as $149 a month. The sources also told the outlet that the deal could also allow Medicare and Medicaid to begin covering the drugs for some patients, including those who are obese or suffering from other high risk health conditions.

The negotiations involve Novo Nordisk’s Wegovy and Eli Lilly’s Zepbo

See Full Page